Sichenzia Ross Ference Kesner LLP Represents Roth Capital Partners and Brookline Securities in a $5.5 Million Public Offering of QBIO Med.

Press Release – New York, NY – February 1, 2018 – Sichenzia Ross Ference Kesner LLP announced today that it has represented Roth Capital Partners LLC as lead Placement Agent and CIM/Brookline Securities, as Co-Lead Placement Agent in a public offering of Common Stock and Warrants Series for QBIO Med, Inc. (OTC.QBIO). QBIO is a biotechnology acceleration and development company focused on acquiring and in-licensing life science therapeutics products.

QBIO received approximately $5.5 million in gross proceeds from the sale of 1,711,875 shares of Common Stock and Common Stock Purchase Warrants sold to the public at a combined price of $3.20 per share. The five year warrants have an exercise price of $3.20 per share. The Common Stock is traded on OTCQB Market under the symbol “QBIO.” The offering is expected to close on or around February 1, 2018, subject to the satisfaction of customary closing conditions.

The Sichenzia Ross Ference Kesner LLP team was led by partners Gregory Sichenzia and Jay Yamamoto.

Author
Recent Posts

Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations. The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation. Additionally, it represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies. The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA). These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct. Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records. The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.

Visit SRFC's LinkedIn page

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in the $8.2 Million Private Placement of SOBRsafe, Inc. - October 8, 2024
Sichenzia Ross Ference Carmel LLP represents A2Z Cust2Mate Solutions Corp. in $4 Million Registered Direct Offering - October 2, 2024
Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.0 Million Offering - October 2, 2024

Sichenzia Ross Ference Kesner LLP Represents Roth Capital Partners and Brookline Securities in a $5.5 Million Public Offering of QBIO Med.

Related Posts